lontucirev
AXP000033.1 · Oncolytic virus
- Platform
- adenovirus (Ad2/Ad5 chimera, E1B-55kDa and E3 deleted)
- Originator
- Onyx Pharmaceuticals
Names
| Name | Type | Source |
|---|---|---|
| lontucirev | preferred name, INN | curator, ncit |
| CI-1042 | code | ncit |
| ONYX-015 | code | ncit |
| E1B 55kDa mutant adenovirus dl1520 | synonym | ncit |
| dl1520 | former code | paper |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad2/Ad5 chimera (dl1520)
- Replication
- conditionally replicating
- Modifications
- E1B-55kDa deleted (nt 2496-3323) plus stop codon at nt 2022; E3 10.4/14.5 and 14.7 deleted
- Route
- intratumoral, intravenous, intra arterial, intraperitoneal
- Source
- evidence
Cross-references
- NCI Thesaurus
- C2830
- FDA UNII
- F1F4B2ILM1
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT00006106 | ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer | Withdrawn | Phase 1 | 1999-07 | 0 | Head and Neck Cancer; Lip and Oral Cavity Cancer; Oropharyngeal Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 36787278 | Randomized Cross-Over Study of In-Vehicle Cabin Air Filtration, Air Pollution Exposure, and Acute Changes to Heart Rate Variability, Saliva Cortisol, and Cognitive Function. | Environmental science & technology | 2023 | name in abstract: CI-1042 |
| PMID 35446353 | Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant. | JAMA oncology | 2022 | name in abstract: CI-1042 |
| PMID 27092831 | Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. | JAMA | 2016 | name in abstract: CI-1042 |
| PMID 19565928 | Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. | Methods in molecular biology (Clifton, N.J.) | 2009 | name in title: ONYX-015 |
| PMID 17139321 | Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. | Cancer gene therapy | 2007 | name in title: ONYX-015 |
| PMID 17704755 | A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. | Cancer gene therapy | 2007 | name in title: ONYX-015 |
| PMID 15596850 | Effects of febrile temperature on adenoviral infection and replication: implications for viral therapy of cancer. | Journal of virology | 2005 | name in abstract: ONYX-015 |
| PMID 15647767 | Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. | Gene therapy | 2005 | name in title: ONYX-015 |
| PMID 15803147 | Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. | Cancer gene therapy | 2005 | name in title: ONYX-015 |
| PMID 15240522 | The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2004 | name in title: dl1520 |
| PMID 15509513 | A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. | Molecular therapy : the journal of the American Society of Gene Therapy | 2004 | name in title: ONYX-015 |
| PMID 12576418 | A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2003 | name in title: ONYX-015 |
| PMID 12576437 | Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2003 | name in title: ONYX-015 |
| PMID 12697873 | Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2003 | name in title: CI-1042 |
| PMID 12719704 | Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. | Cancer gene therapy | 2003 | name in title: ONYX-015 |
| PMID 14597742 | An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2003 | name in title: ONYX-015 |
| PMID 11896105 | Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2002 | name in title: ONYX-015 |
| PMID 11896441 | Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. | Cancer gene therapy | 2002 | name in title: dl1520 |
| PMID 12414631 | Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. | Cancer research | 2002 | name in title: dl1520 |
| PMID 11177559 | E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. | Human gene therapy | 2001 | name in title: dl1520 |
| PMID 11208818 | Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2001 | name in title: ONYX-015 |
| PMID 11313805 | Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. | Gene therapy | 2001 | name in title: ONYX-015 |
| PMID 11420638 | Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. | Gene therapy | 2001 | name in title: ONYX-015 |
| PMID 11895000 | Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. | Gene therapy | 2001 | name in title: dl1520 |
| PMID 10741699 | A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2000 | name in title: ONYX-015 |
| PMID 10932224 | a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. | Nature medicine | 2000 | name in title: ONYX-015 |
| PMID 11005557 | A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). | Annals of surgical oncology | 2000 | name in title: ONYX-015 |
| PMID 11103798 | Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. | Cancer research | 2000 | name in title: ONYX-015 |
| PMID 9717985 | Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team. | British journal of cancer | 1998 | name in abstract: ONYX-015 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41494693 | Previous tuberculosis modifies spirometry outcomes among small-scale gemstone miners in Tanzania: a cross-sectional, clinic-based study. | BMJ open respiratory research | 2026 | name in abstract: CI-1042 |
| PMID 42602576 | The new normal: Simultaneous temporal increases in workload and physician well-being experienced by Stanford pathology in a transformed work environment. | Academic pathology | 2026 | name in abstract: CI-1042 |
| PMID 42870782 | Global research trends in oncolytic virotherapy for sarcomas of bone and soft tissue (2000-2024): a bibliometric and visualization study. | Translational cancer research | 2026 | name in abstract: ONYX-015 |
| PMID 38837373 | Gene therapy for people with hepatocellular carcinoma. | The Cochrane database of systematic reviews | 2024 | name in abstract: dl1520 |
| PMID 36299168 | Oncolytic virus preclinical toxicology studies. | Journal of applied toxicology : JAT | 2023 | name in abstract: ONYX-015 |
| PMID 37087299 | Cost-utility of Ranolazine for Chronic Stable Angina Pectoris: Systematic Review and Meta-analysis. | Clinical therapeutics | 2023 | name in abstract: CI-1042 |
| PMID 37293562 | Chemoprevention in oral leukoplakia: challenges and current landscape. | Frontiers in oral health | 2023 | name in abstract: ONYX-015 |
| PMID 38135348 | Commentary on oncolytic viruses: past, present, and future. | Journal for immunotherapy of cancer | 2023 | name in abstract: ONYX-015 |
| PMID 35002022 | Restructuring the ONYX-015 adenovirus by using spike protein genes from SARS-CoV-2 and MERS-CoV: Possible implications in breast cancer treatment. | Medical hypotheses | 2022 | name in title: ONYX-015 |
| PMID 35596069 | Ixovex-1, a novel oncolytic E1B-mutated adenovirus. | Cancer gene therapy | 2022 | name in abstract: ONYX-015 |
| PMID 35756634 | Role of Adenoviruses in Cancer Therapy. | Frontiers in oncology | 2022 | name in abstract: ONYX-015 |
| PMID 34155929 | Optimization of the Administration Strategy for the Armed Oncolytic Adenovirus ZD55-IL-24 in Both Immunocompromised and Immunocompetent Mouse Models. | Human gene therapy | 2021 | name in abstract: ONYX-015 |
| PMID 32125404 | Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. | JAMA | 2020 | name in abstract: CI-1042 |
| PMID 33257647 | The armed oncolytic adenovirus ZD55-IL-24 eradicates melanoma by turning the tumor cells from the self-state into the nonself-state besides direct killing. | Cell death & disease | 2020 | name in abstract: ONYX-015 |
| PMID 30919653 | Biomarkers of nondipper hypertension in prehypertensive and hypertensive patients. | Biomarkers in medicine | 2019 | name in abstract: CI-1042 |
| PMID 31933185 | Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma. | Pharmaceutical medicine | 2019 | name in abstract: ONYX-015 |
| PMID 28929492 | Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer. | International journal of cancer | 2018 | name in abstract: ONYX-015 |
| PMID 29900755 | Exploring the role of oncolytic viruses in hepatobiliary cancers. | Immunotherapy | 2018 | name in abstract: dl1520 |
| PMID 28631589 | Comparison of protein expression during wild-type, and E1B-55k-deletion, adenovirus infection using quantitative time-course proteomics. | The Journal of general virology | 2017 | name in abstract: dl1520 |
| PMID 26429639 | Synergistic cytotoxicity against human tumor cell lines by oncolytic adenovirus dl1520 (ONYX-015) and melphalan. | Tumori | 2016 | name in title: ONYX-015 |
| PMID 27391605 | Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector. | PloS one | 2016 | name in abstract: ONYX-015 |
| PMID 25376708 | Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter. | Journal of molecular medicine (Berlin, Germany) | 2015 | name in abstract: ONYX-015 |
| PMID 25560085 | Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. | Molecular oncology | 2015 | name in abstract: dl1520 |
| PMID 26280277 | Going viral: a review of replication-selective oncolytic adenoviruses. | Oncotarget | 2015 | name in abstract: ONYX-015 |
| PMID 25093639 | ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models. | Human gene therapy | 2014 | name in abstract: ONYX-015 |
| PMID 25364261 | Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. | OncoTargets and therapy | 2014 | name in abstract: ONYX-015 |
| PMID 23596535 | Tumors and new endoscopic ultrasound-guided therapies. | World journal of gastrointestinal endoscopy | 2013 | name in abstract: ONYX-015 |
| PMID 24124726 | Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells. | Journal of translational medicine | 2013 | name in abstract: dl1520 |
| PMID 24136729 | Tumor-specific cytolysis caused by an E1B55K-attenuated adenovirus in nasopharyngeal carcinoma is augmented by cisplatin. | Anatomical record (Hoboken, N.J. : 2007) | 2013 | name in abstract: dl1520 |
| PMID 22238308 | Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. | Journal of virology | 2012 | name in abstract: dl1520 |
| PMID 22321574 | Targeting Gene-Viro-Therapy with AFP driving Apoptin gene shows potent antitumor effect in hepatocarcinoma. | Journal of biomedical science | 2012 | name in abstract: ONYX-015 |
| PMID 22880939 | Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. | Expert opinion on therapeutic targets | 2012 | name in abstract: ONYX-015 |
| PMID 23141400 | [Antitumour efficacy of a novel oncolytic adenovirus Ad-TD-RFP for human nasopharyngeal carcinoma]. | Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery | 2012 | name in abstract: dl1520 |
| PMID 21361787 | Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer. | Human gene therapy | 2011 | name in title: ONYX-015 |
| PMID 21379332 | A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition. | PLoS computational biology | 2011 | name in abstract: ONYX-015 |
| PMID 21818136 | Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b. | Cancer gene therapy | 2011 | name in abstract: ONYX-015 |
| PMID 21836633 | An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. | Cancer gene therapy | 2011 | name in abstract: dl1520 |
| PMID 21975464 | The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. | Gene therapy | 2011 | name in abstract: ONYX-015 |
| PMID 20165905 | Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24. | Molecular and cellular biochemistry | 2010 | name in abstract: ONYX-015 |
| PMID 20497039 | Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. | Human gene therapy | 2010 | name in abstract: dl1520 |
| PMID 20574150 | The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus. | Cancer biology & therapy | 2010 | name in abstract: ONYX-015 |
| PMID 20596091 | A fully replication-competent adenovirus vector with enhanced oncolytic properties. | Cancer gene therapy | 2010 | name in abstract: ONYX-015 |
| PMID 20598155 | p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. | Molecular cancer | 2010 | name in abstract: ONYX-015 |
| PMID 21103299 | EUS-Guided Antitumor Therapy for Pancreatic Tumors. | Gut and liver | 2010 | name in abstract: ONYX-015 |
| PMID 19129452 | E4orf1 limits the oncolytic potential of the E1B-55K deletion mutant adenovirus. | Journal of virology | 2009 | name in abstract: ONYX-015 |
| PMID 19407849 | RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses. | Cancer gene therapy | 2009 | name in abstract: ONYX-015 |
| PMID 19458647 | In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of ColoAd1-based treatment of cancer. | Gene therapy | 2009 | name in abstract: ONYX-015 |
| PMID 19481338 | E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. | Cancer letters | 2009 | name in abstract: ONYX-015 |
| PMID 19860656 | Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. | Current gene therapy | 2009 | name in abstract: ONYX-015 |
| PMID 18071311 | Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. | Oncogene | 2008 | name in abstract: ONYX-015 |
| PMID 18300357 | Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma. | World journal of gastroenterology | 2008 | name in abstract: ONYX-015 |
| PMID 18560559 | Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. | PloS one | 2008 | name in abstract: ONYX-015 |
| PMID 18618506 | Significant antitumor activity of oncolytic adenovirus expressing human interferon-beta for hepatocellular carcinoma. | The journal of gene medicine | 2008 | name in abstract: ONYX-015 |
| PMID 18683102 | Virus combinations and chemotherapy for the treatment of human cancers. | Current opinion in molecular therapeutics | 2008 | name in abstract: ONYX-015 |
| PMID 18710328 | Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. | Human gene therapy | 2008 | name in abstract: ONYX-015 |
| PMID 18771358 | Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions. | Human gene therapy | 2008 | name in abstract: ONYX-015 |
| PMID 18927290 | Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2008 | name in abstract: dl1520 |
| PMID 17008933 | Potent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis. | Cancer gene therapy | 2007 | name in abstract: ONYX-015 |
| PMID 17079297 | Adenovirus ubiquitin-protein ligase stimulates viral late mRNA nuclear export. | Journal of virology | 2007 | name in abstract: dl1520 |
| PMID 17095020 | Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus. | Journal of theoretical biology | 2007 | name in title: ONYX-015 |
| PMID 17300834 | Cancer selective adenoviruses. | Molecular aspects of medicine | 2007 | name in abstract: ONYX-015 |
| PMID 17346104 | From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. | Current cancer drug targets | 2007 | name in title: ONYX-015 |
| PMID 17518613 | Modification of the Rb-binding domain of replication-competent adenoviral vector enhances cytotoxicity against human esophageal cancers via NF-kappaB activity. | Human gene therapy | 2007 | name in abstract: ONYX-015 |
| PMID 17577631 | Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. | Molecular and cellular biochemistry | 2007 | name in abstract: ONYX-015 |
| PMID 17690162 | Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. | Endocrinology | 2007 | name in title: dl1520 |
| PMID 17965776 | Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. | The Journal of clinical investigation | 2007 | name in abstract: ONYX-015 |
| PMID 18031615 | Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus. | Acta pharmacologica Sinica | 2007 | name in abstract: ONYX-015 |
| PMID 18473990 | Molecular targeting in pancreatic cancer. | Reviews on recent clinical trials | 2007 | name in abstract: ONYX-015 |
| PMID 16247442 | p53 promotes adenoviral replication and increases late viral gene expression. | Oncogene | 2006 | name in abstract: ONYX-015 |
| PMID 16341141 | Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells. | Cancer gene therapy | 2006 | name in abstract: dl1520 |
| PMID 16421637 | E1A genes of adenovirus type 2 and type 5 are expressed at different levels. | Archives of virology | 2006 | name in abstract: ONYX-015 |
| PMID 16424034 | Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. | Cancer research | 2006 | name in abstract: dl1520 |
| PMID 16467873 | Targeting gene-virotherapy of cancer. | Cell research | 2006 | name in abstract: ONYX-015 |
| PMID 16636723 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2006 | name in abstract: ONYX-015 |
| PMID 16690321 | p53 as a target for anti-cancer drug development. | Critical reviews in oncology/hematology | 2006 | name in abstract: ONYX-015 |
| PMID 16760273 | Apoptosis: a relevant tool for anticancer therapy. | Annals of oncology : official journal of the European Society for Medical Oncology | 2006 | name in abstract: ONYX-015 |
| PMID 16969092 | E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells. | Cell cycle (Georgetown, Tex.) | 2006 | name in title: ONYX-015 |
| PMID 16971969 | Adenoviral gene therapy in head and neck cancer. | Drug news & perspectives | 2006 | name in abstract: ONYX-015 |
| PMID 17102812 | Targeting gene-virotherapy of cancer and its prosperity. | Cell research | 2006 | name in abstract: ONYX-015 |
| PMID 17121717 | [Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University | 2006 | name in abstract: ONYX-015 |
| PMID 17167712 | Reovirus - possible therapy of cancer. | Neoplasma | 2006 | name in abstract: ONYX-015 |
| PMID 17171789 | Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma. | World journal of gastroenterology | 2006 | name in abstract: ONYX-015 |
| PMID 15389517 | Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma. | International journal of cancer | 2005 | name in abstract: ONYX-015 |
| PMID 15740644 | Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinoma. | Chinese medical journal | 2005 | name in abstract: ONYX-015 |
| PMID 15762988 | Heat shock protein 72 expression allows permissive replication of oncolytic adenovirus dl1520 (ONYX-015) in rat glioblastoma cells. | Molecular cancer | 2005 | name in title: ONYX-015 |
| PMID 15771958 | Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. | Molecular therapy : the journal of the American Society of Gene Therapy | 2005 | name in abstract: ONYX-015 |
| PMID 15814661 | The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2005 | name in title: dl1520 |
| PMID 15818382 | The potential of oncolytic virus therapy for pancreatic cancer. | Cancer gene therapy | 2005 | name in abstract: ONYX-015 |
| PMID 15854553 | [hTERT promoter regulated replication-selective adenovirus CNHK300 in treatment of hepatocellular carcinoma]. | Zhonghua yi xue za zhi | 2005 | name in abstract: ONYX-015 |
| PMID 15920462 | Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. | Gene therapy | 2005 | name in abstract: ONYX-015 |
| PMID 15946541 | [CNHK200-hA-a gene-viral therapeutic system and its antitumor effect on lung cancer]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] | 2005 | name in abstract: ONYX-015 |
| PMID 16000066 | Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. | Human gene therapy | 2005 | name in abstract: ONYX-015 |
| PMID 16023599 | Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. | Cancer cell | 2005 | name in title: ONYX-015 |
| PMID 16101516 | The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? | Current gene therapy | 2005 | name in abstract: ONYX-015 |
| PMID 16155833 | [Effect of replication- competent adenovirus-mediated interleukin- 12 gene to chemotherapeutic sensitivity on gastric cancer cell]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery | 2005 | name in abstract: ONYX-015 |
| PMID 16299526 | Viruses - seeking and destroying the tumor program. | Oncogene | 2005 | name in abstract: ONYX-015 |
| PMID 16555996 | Cancer scene investigation: how a cold virus became a tumor killer. | Future oncology (London, England) | 2005 | name in abstract: dl1520 |
| PMID 16556054 | Elucidation of the molecular mechanism underlying tumor-selective replication of the oncolytic adenovirus mutant ONYX-015. | Future oncology (London, England) | 2005 | name in title: ONYX-015 |
| PMID 19202637 | Clinical trials: the sensitizing side of ONYX-015. | Gene therapy | 2005 | name in title: ONYX-015 |
| PMID 34679293 | [Insights into a new weapon against cancer: oncolytic viruses]. | Virologie (Montrouge, France) | 2005 | name in abstract: ONYX-015 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01CA137094 | Defining Critical p53 Therapeutic Targets and Mechanisms | SALK INSTITUTE FOR BIOLOGICAL STUDIES | O'SHEA, CLODAGH | 2009–2019 | name in abstract: ONYX-015 |
| R01CA129975 | Adenovirus E1B55K Functions Related to Oncolytic Replication | UNIVERSITY OF LOUISVILLE | ZHOU, HESHAN SAM | 2009–2012 | name in abstract: dl1520 |
| P41RR001614 | ID OF NOVEL CELLULAR & VIRAL PARTNERS OF THE ADENOVIRUS L4 100K PROTEIN | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | MCCORMICK, FRANK PATRICK | 2006–2011 | name in abstract: ONYX-015 |
| R01CA064799 | Mechanism of p53 Silencing By Adenovirus E1B 55K Protein | UNIVERSITY OF CALIFORNIA LOS ANGELES | BERK, ARNOLD J | 2007–2011 | name in abstract: ONYX-015 |
| RC2CA148099 | Clinical evaluation of a bioadhesive gel for oral cancer chemoprevention. | OHIO STATE UNIVERSITY | MALLERY, SUSAN R | 2009–2010 | name in project terms: ONYX-015 |
| P50CA114747 | Dual Biotherapy for the Treatment of Malignancy | STANFORD UNIVERSITY | GAMBHIR, SANJIV S | 2007–2009 | name in project terms: ONYX-015 |
| R01CA118545 | Experimentally Validated Mathematical Modeling of Oncolytic Virus Infection | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | KORN, WOLFGANG MICHAEL | 2006–2009 | name in abstract: ONYX-015 |
| R42CA114921 | Cancer dual-targeting of an infectivity-enhance CRAd | VECTORLOGICS, INC. | MATHIS, J. MICHAEL | 2008–2009 | name in project terms: ONYX-015 |
| R01EY013812 | Improved Ophthalmic Care for Retinoblastoma Patients | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | O'BRIEN, JOAN M | 2002–2007 | name in abstract: ONYX-015 |
| M01RR000079 | C98-118-01: SCH58500 & chemotherapy in colorectal cancer metastatic to liver | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | VENOOK, ALAN PAUL | 1997–2003 | name in title: ONYX-015 |
| M01RR001346 | PHASE I TRIAL OF INTRATUMORAL INJECTION OF ONYX-015 INTO HEAD, NECK TUMORS | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER | VON HOFF, DANIEL D | 1998–1999 | name in title: ONYX-015 |
| R43CA081889 | ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 FOR TUMOR THERAPY | ONYX PHARMACEUTICALS, INC. | LAQUERRE, SYLVIE | 1999–1999 | name in abstract: ONYX-015 |
Notes
First engineered oncolytic virus in human trials (1996). Development as ONYX-015 was stopped by Onyx/Pfizer in 2003; the closely related Chinese construct H101 (AXP000003) was approved instead. INN lontucirev is rarely used; ONYX-015 is the common name.
How to cite
lontucirev (AXP000033.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000033.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.